NCT06224257招募中2 期
A Phase 2, Multicenter, Single-arm, Open-label Study on the Efficacy and Safety of PI3K Inhibitors in Relapsed/Refractory Large Granular T Lymphocytic Leukemia
Institute of Hematology & Blood Diseases Hospital, China3 个研究点 分布在 1 个国家目标入组 41 人开始时间: 2023年12月3日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 41
- 试验地点
- 3
- 主要终点
- Proportion of patients with hematologic remission
研究概览
简要总结
This is a prospective, multicenter, single-arm, phase 2 study. This study aims to evaluate the efficacy and safety of Linperlisib, the PI3K delta inhibitor for patients with relapsed/refractory large granular T lymphocytic leukemia.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female age ≥ 18 years
- •Diagnosis of T-cell large granular lymphocytic leukemia (T-LGLL)
- •Meet any of the following indications for treatment：
- •Hemoglobin < 100g/L or RBC transfusion dependence
- •Neutrophil count <0.5×10^9/L or neutrophil count decreased with recurrent infection
- •Progressive splenomegaly and/or Massive Splenomegaly
- •Combined with autoimmune diseases requiring treatment, such as rheumatoid arthritis, autoimmune thyroiditis, etc.
- •Severe B symptoms
- •Failure or intolerance to a first-line therapy
- •ECOG performance status ≤2
- •Expected survival ≥ 6 months
- •Willing and able to comply with the requirements for this study and written informed consent
排除标准
- •History of other lymphoproliferative neoplasms
- •Had malignant tumor within 5 years before enrollment, exclusive of cured basal or squamous cell skin cancer, superficial bladder cancer, prostate intraepithelial tumor, cervical carcinoma in situ or other indolent tumors
- •Previously received organ or stem cell transplantation
- •Patients with active infection within 2 weeks before giving the first dose of medication
- •Patients with HBV, HCV, HIV or other infections that require treatment
- •History of immunodeficiency, or congenital immunodeficiency disorders
- •Any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study, including clinically significant cardiac diseases, refractory hypertension, metabolic disorders and other diseases that seriously affect the function of the gastrointestinal tract.
- •Abnormal liver function: two consecutive examinations with an interval of ≥1 week suggest that ALT and AST are 2.5 times higher than the upper limit of normal values
- •Renal impairment: creatinine clearance <30ml/min
- •History of mental illness
- •History of pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug-related pneumonia, severe impairment of lung function, etc.
- •Received attenuated vaccine 4 in weeks before enrollment
- •Participation in another clinical trial within 4 weeks before the start of this trial
- •Have an allergy to Linperlisib or any other part of this medicine.
- •Pregnant or breast-feeding patients
- •Patients considered to be ineligible for the study by the investigator for reasons other than the above
研究组 & 干预措施
Linperlisib
Experimental
Linperlisib was administered at 80 mg every day, orally in a 28-day cycle until disease progression or intolerable toxicity occurred.
干预措施: Linperlisib (Drug)
结局指标
主要结局
Proportion of patients with hematologic remission
时间窗: 8-12 weeks
Hematological response is evaluated by hemoglobin (Hb), absolute neutrophil count (ANC), platelet count (PLT), absolute lymphocyte count (ALC), absolute large granular lymphocyte count, and blood transfusion.
次要结局
- Incidence of the adverse event(8-12 weeks)
研究者
研究点 (3)
Loading locations...
相似试验
尚未招募
2 期
Nab-paclitaxel in Combination With Pyrotinib in Postoperative Adjuvant Therapy for HER2-positive Breast CancerEarly Breast CancerNCT04659499Peking Union Medical College Hospital261
尚未招募
2 期
A Phase II Study of Rulonilimab Combined With Chemotherapy in the First-Line Treatment for Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)PD-1Non-small Cell Lung CancerNSCLCNCT05741021Shandong New Time Pharmaceutical Co., LTD84
招募中
2 期
Cadonilimab and Lenvatinib for Conversion Therapy in Unresectable Hepatocellular CarcinomaCadonilimab and LenvatinibNCT06215651Peking Union Medical College Hospital30
已完成
不适用
Effect of Tumor Treating Fields (TTFields, 150 KHz) Concomitant with Chemotherapy As First Line Treatment of Unresectable Gastroesophageal Junction or Gastric AdenocarcinomaGastroEsophageal CancerGastric CancerNCT04281576NovoCure Ltd.28
Unknown
2 期
A Phase II Study to Evaluate the Efficacy and Safety of F520 Combined With F007 in Patients With RR DLBCLRR DLBCL; PD-1; CD20NCT05178836Shandong New Time Pharmaceutical Co., LTD62